Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
Current treatment recommendations are based on very limited evidence and reliant on the deployment of pharmacological strategies of doubtful efficacy, high toxicity, and near universal shortages of supply. On a global scale, there is a desperate need for readily available therapeutic options to safely and cost effectively target the hyper-inflammatory state in ICU patients based on management of severe COVID-19 (evidence of acute respiratory distress syndrome). The study team proposes to use slow low-efficiency daily dialysis to provide an extracorporeal circuit to target this cytokine storm using immunomodulation of neutrophils with a novel leucocyte modulatory device (L-MOD) to generate an anti-inflammatory phenotype, but without depletion of circulating factors.
Description: Efficacy will be evaluated by reduction of vasopressor support (converted to norepinephrine dose equivalents) compared to control group.
Measure: Efficacy of a L-MOD against controls receiving supportive care in ICU. Time: Through dialysis, on average of 12 hours, two days in a rowDescription: Time to ICU and hospital discharge compared to case-matched controls
Measure: Mortality Time: From date of randomization until the date of death from any cause, whichever came first, assessed up to 2 monthsDescription: Time to ICU and hospital discharge compared to case-matched controls
Measure: Hospital Discharge Time: From date of randomization until the date of hospital discharge or death from any cause, whichever came first, assessed up to 2 monthsDescription: Over the course of the disease white blood cells will be monitored (i.e. neutrophils, macrophages...)
Measure: Leukocyte Monitoring Time: Through dialysis, on average of 12 hours, two days in a row and again on day 5 in the ICUDescription: Evolution of the Sequential Organ Failure Assessment (SOFA) score. The SOFA score ranges from 0 to 24. The higher score means the worst outcome.
Measure: Sequential Organ Failure Assessment (SOFA) Score Time: From date of randomization until the date of ICU discharge or death from any cause, whichever came first, assessed up to 1 monthsDescription: intubation length will be recorded (in day)
Measure: Intubation length Time: From date of randomization until the date of ICU discharge up to 2 monthsDescription: Evolution of hsCRP during dialysis treatment
Measure: Markers of Inflammation Time: Through dialysis, on average of 12 hours, two days in a row and again after day 4 and no later than day 7 in the ICUDescription: Characterization of activated/desactivated leukocyte and macrophage subsets in the blood
Measure: Leukocytes and Macrophages Time: Through dialysis, on average of 12 hours, two days in a row and again after day 4 and no later than day 7 in the ICUDescription: Myocardial damage will be assessed by troponin measurement (ng/mL)
Measure: Myocardial damage Time: From date of randomization until the date of ICU discharge up to 2 monthsDescription: Renal recovery will be assessed by serum creatinin measurement (micromol/L)
Measure: Renal recovery Time: From date of randomization until the date of ICU discharge up to 2 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports